February 27, 2015

AVEO Oncology to Host Conference Call to Discuss Presentation of Final Results and Biomarker Analysis from Phase 2 Study of Tivozanib in Patients with Advanced Colorectal Cancer

Download PDF

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 27, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call and webcast on Friday, March 6, 2015, at 8:00 a.m. Eastern Time to discuss the presentation of final results and a predefined biomarker analysis of its BATON-CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer. The presentation, titled “Neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib + mFOLFOX6 versus bevacizumab + mFOLFOX6 in metastatic colorectal cancer: post-hoc biomarker analysis of BATON-CRC Phase 2 trial,” will be presented in a poster session on March 6 at the American Association for Cancer Research (AACR) Tumor Angiogenesis and Vascular Normalization Conference in Orlando, FL.

The call can be accessed by dialing 1-877-280-4954 (domestic) or 1-857-244-7311 (international) five minutes prior to the start of the call and providing the passcode 38640881. A replay of the call will be available two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 54500453. The replay will be available for two weeks from the date of the live call.

The live webcast of the conference call can be accessed by visiting the investors section of the AVEO website at www.aveooncology.com. A replay of the webcast will be archived on the AVEO website for two weeks following the call.

A copy of the poster presentation will be made available on AVEO’s website at www.aveooncology.com.

About AVEO

AVEO Oncology (NASDAQ:AVEO) is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide improvements in patient outcomes where significant unmet medical needs exist. AVEO’s proprietary Human Response Platform™ has delivered unique insights into cancer and related disease biology that are being leveraged in the clinical development strategy of its therapeutic candidates. For more information, please visit the company’s website at www.aveooncology.com.

Source: AVEO Oncology

Company, Media and Investor Contact:
Argot Partners
David Pitts, 212-600-1902